Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic

Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel ant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC research notes 2016-07, Vol.9 (1), p.337-337, Article 337
Hauptverfasser: Cheung Lam, Annie H, Sandoval, Natalie, Wadhwa, Ritambhara, Gilkes, Janine, Do, Thai Q, Ernst, William, Chiang, Su-Ming, Kosina, Suzanne, Howard Xu, H, Fujii, Gary, Porter, Edith
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 337
container_issue 1
container_start_page 337
container_title BMC research notes
container_volume 9
creator Cheung Lam, Annie H
Sandoval, Natalie
Wadhwa, Ritambhara
Gilkes, Janine
Do, Thai Q
Ernst, William
Chiang, Su-Ming
Kosina, Suzanne
Howard Xu, H
Fujii, Gary
Porter, Edith
description Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria. Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed. Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h. Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.
doi_str_mv 10.1186/s13104-016-2138-8
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4938966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468885761</galeid><sourcerecordid>A468885761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</originalsourceid><addsrcrecordid>eNptkk-LFDEQxRtR3HX1A3iRgBc99JqadCfpizAs_llY2It6DemkMhtJd8aunsH59qadddkByaFC5VePeuFV1WvglwBafiAQwJuag6xXIHStn1TnoFpZ85bzp4_uZ9ULop-cS9AanldnKyU6aPjqvIprIiQacJxZDixMiCzYeT4w66InZkfP3F1OSDNOh8T-VmIeU9zjhJ7FkaW4zZQHLDSxMe8xMZcs0SJoxzn2Mc_RvayeBZsIX93Xi-r750_frr7WN7dfrq_WN7VroNV1jysrXIdeWOXa3jWyUyEIwYWySnKnLCJ4dKoP4EPrReOhEdBa37atlr24qD4edbe7fkDvirPJJrOd4mCng8k2mtOXMd6ZTd6bphO6k7IIvLsXmPKvXTFshkgOU7Ij5h0Z0GWXTsmVLujbI7qxCU0cQy6KbsHNupFa61ZJKNTlf6hyPA7R5RFDLP2TgfcnA4WZ8fe8sTsic33745SFI-umTDRheHAK3CwpMceUmJISs6TELGu_efxFDxP_YiH-AJz4uP8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1803797628</pqid></control><display><type>article</type><title>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cheung Lam, Annie H ; Sandoval, Natalie ; Wadhwa, Ritambhara ; Gilkes, Janine ; Do, Thai Q ; Ernst, William ; Chiang, Su-Ming ; Kosina, Suzanne ; Howard Xu, H ; Fujii, Gary ; Porter, Edith</creator><creatorcontrib>Cheung Lam, Annie H ; Sandoval, Natalie ; Wadhwa, Ritambhara ; Gilkes, Janine ; Do, Thai Q ; Ernst, William ; Chiang, Su-Ming ; Kosina, Suzanne ; Howard Xu, H ; Fujii, Gary ; Porter, Edith</creatorcontrib><description>Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria. Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed. Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h. Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.</description><identifier>ISSN: 1756-0500</identifier><identifier>EISSN: 1756-0500</identifier><identifier>DOI: 10.1186/s13104-016-2138-8</identifier><identifier>PMID: 27391402</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Care and treatment ; Cholesterol Esters - pharmacology ; Cross Infection - drug therapy ; DNA, Bacterial - analysis ; DNA, Bacterial - genetics ; Drug Combinations ; Drug Compounding ; Drug Resistance, Multiple, Bacterial ; Drug Synergism ; Enterococcus faecalis - drug effects ; Enterococcus faecalis - genetics ; Enterococcus faecalis - growth &amp; development ; Erythrocytes - drug effects ; Esters ; Fatty acids ; Fatty Acids, Nonesterified - pharmacology ; Fluorescent Dyes ; Health aspects ; Hemolysis - drug effects ; Hep G2 Cells ; Humans ; Liposomes - chemistry ; Microbial drug resistance ; Microbial Sensitivity Tests ; Organic Chemicals ; Properties ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - genetics ; Pseudomonas aeruginosa - growth &amp; development ; Sheep ; Staphylococcus epidermidis - drug effects ; Staphylococcus epidermidis - genetics ; Staphylococcus epidermidis - growth &amp; development ; Vancomycin - pharmacology</subject><ispartof>BMC research notes, 2016-07, Vol.9 (1), p.337-337, Article 337</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</citedby><cites>FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938966/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938966/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27391402$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung Lam, Annie H</creatorcontrib><creatorcontrib>Sandoval, Natalie</creatorcontrib><creatorcontrib>Wadhwa, Ritambhara</creatorcontrib><creatorcontrib>Gilkes, Janine</creatorcontrib><creatorcontrib>Do, Thai Q</creatorcontrib><creatorcontrib>Ernst, William</creatorcontrib><creatorcontrib>Chiang, Su-Ming</creatorcontrib><creatorcontrib>Kosina, Suzanne</creatorcontrib><creatorcontrib>Howard Xu, H</creatorcontrib><creatorcontrib>Fujii, Gary</creatorcontrib><creatorcontrib>Porter, Edith</creatorcontrib><title>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</title><title>BMC research notes</title><addtitle>BMC Res Notes</addtitle><description>Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria. Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed. Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h. Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Care and treatment</subject><subject>Cholesterol Esters - pharmacology</subject><subject>Cross Infection - drug therapy</subject><subject>DNA, Bacterial - analysis</subject><subject>DNA, Bacterial - genetics</subject><subject>Drug Combinations</subject><subject>Drug Compounding</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug Synergism</subject><subject>Enterococcus faecalis - drug effects</subject><subject>Enterococcus faecalis - genetics</subject><subject>Enterococcus faecalis - growth &amp; development</subject><subject>Erythrocytes - drug effects</subject><subject>Esters</subject><subject>Fatty acids</subject><subject>Fatty Acids, Nonesterified - pharmacology</subject><subject>Fluorescent Dyes</subject><subject>Health aspects</subject><subject>Hemolysis - drug effects</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Liposomes - chemistry</subject><subject>Microbial drug resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Organic Chemicals</subject><subject>Properties</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - genetics</subject><subject>Pseudomonas aeruginosa - growth &amp; development</subject><subject>Sheep</subject><subject>Staphylococcus epidermidis - drug effects</subject><subject>Staphylococcus epidermidis - genetics</subject><subject>Staphylococcus epidermidis - growth &amp; development</subject><subject>Vancomycin - pharmacology</subject><issn>1756-0500</issn><issn>1756-0500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkk-LFDEQxRtR3HX1A3iRgBc99JqadCfpizAs_llY2It6DemkMhtJd8aunsH59qadddkByaFC5VePeuFV1WvglwBafiAQwJuag6xXIHStn1TnoFpZ85bzp4_uZ9ULop-cS9AanldnKyU6aPjqvIprIiQacJxZDixMiCzYeT4w66InZkfP3F1OSDNOh8T-VmIeU9zjhJ7FkaW4zZQHLDSxMe8xMZcs0SJoxzn2Mc_RvayeBZsIX93Xi-r750_frr7WN7dfrq_WN7VroNV1jysrXIdeWOXa3jWyUyEIwYWySnKnLCJ4dKoP4EPrReOhEdBa37atlr24qD4edbe7fkDvirPJJrOd4mCng8k2mtOXMd6ZTd6bphO6k7IIvLsXmPKvXTFshkgOU7Ij5h0Z0GWXTsmVLujbI7qxCU0cQy6KbsHNupFa61ZJKNTlf6hyPA7R5RFDLP2TgfcnA4WZ8fe8sTsic33745SFI-umTDRheHAK3CwpMceUmJISs6TELGu_efxFDxP_YiH-AJz4uP8</recordid><startdate>20160708</startdate><enddate>20160708</enddate><creator>Cheung Lam, Annie H</creator><creator>Sandoval, Natalie</creator><creator>Wadhwa, Ritambhara</creator><creator>Gilkes, Janine</creator><creator>Do, Thai Q</creator><creator>Ernst, William</creator><creator>Chiang, Su-Ming</creator><creator>Kosina, Suzanne</creator><creator>Howard Xu, H</creator><creator>Fujii, Gary</creator><creator>Porter, Edith</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160708</creationdate><title>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</title><author>Cheung Lam, Annie H ; Sandoval, Natalie ; Wadhwa, Ritambhara ; Gilkes, Janine ; Do, Thai Q ; Ernst, William ; Chiang, Su-Ming ; Kosina, Suzanne ; Howard Xu, H ; Fujii, Gary ; Porter, Edith</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4158-be2a3c9ed3a7c5bc4697ff33037a760c7aee1dec7bf1df5d34d14315ad55586b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Care and treatment</topic><topic>Cholesterol Esters - pharmacology</topic><topic>Cross Infection - drug therapy</topic><topic>DNA, Bacterial - analysis</topic><topic>DNA, Bacterial - genetics</topic><topic>Drug Combinations</topic><topic>Drug Compounding</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug Synergism</topic><topic>Enterococcus faecalis - drug effects</topic><topic>Enterococcus faecalis - genetics</topic><topic>Enterococcus faecalis - growth &amp; development</topic><topic>Erythrocytes - drug effects</topic><topic>Esters</topic><topic>Fatty acids</topic><topic>Fatty Acids, Nonesterified - pharmacology</topic><topic>Fluorescent Dyes</topic><topic>Health aspects</topic><topic>Hemolysis - drug effects</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Liposomes - chemistry</topic><topic>Microbial drug resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Organic Chemicals</topic><topic>Properties</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - genetics</topic><topic>Pseudomonas aeruginosa - growth &amp; development</topic><topic>Sheep</topic><topic>Staphylococcus epidermidis - drug effects</topic><topic>Staphylococcus epidermidis - genetics</topic><topic>Staphylococcus epidermidis - growth &amp; development</topic><topic>Vancomycin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung Lam, Annie H</creatorcontrib><creatorcontrib>Sandoval, Natalie</creatorcontrib><creatorcontrib>Wadhwa, Ritambhara</creatorcontrib><creatorcontrib>Gilkes, Janine</creatorcontrib><creatorcontrib>Do, Thai Q</creatorcontrib><creatorcontrib>Ernst, William</creatorcontrib><creatorcontrib>Chiang, Su-Ming</creatorcontrib><creatorcontrib>Kosina, Suzanne</creatorcontrib><creatorcontrib>Howard Xu, H</creatorcontrib><creatorcontrib>Fujii, Gary</creatorcontrib><creatorcontrib>Porter, Edith</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC research notes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung Lam, Annie H</au><au>Sandoval, Natalie</au><au>Wadhwa, Ritambhara</au><au>Gilkes, Janine</au><au>Do, Thai Q</au><au>Ernst, William</au><au>Chiang, Su-Ming</au><au>Kosina, Suzanne</au><au>Howard Xu, H</au><au>Fujii, Gary</au><au>Porter, Edith</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic</atitle><jtitle>BMC research notes</jtitle><addtitle>BMC Res Notes</addtitle><date>2016-07-08</date><risdate>2016</risdate><volume>9</volume><issue>1</issue><spage>337</spage><epage>337</epage><pages>337-337</pages><artnum>337</artnum><issn>1756-0500</issn><eissn>1756-0500</eissn><abstract>Healthcare associated infections (HAI) with multidrug-resistant (MDR) bacteria continue to be a global threat, highlighting an urgent need for novel antibiotics. In this study, we assessed the potential of free fatty acids and cholesteryl esters that form part of the innate host defense as novel antibacterial agents for use against MDR bacteria. Liposomes of six different phospholipid mixtures were employed as carrier for six different fatty acids and four different cholesteryl esters. Using a modified MIC assay based on DNA quantification with the fluoroprobe Syto9, formulations were tested against Gram-positive and Gram-negative bacteria implicated in HAI. Formulations with MIC values in the low μg/mL range were further subjected to determination of minimal bactericidal activity, hemolysis assay with sheep erythrocytes, and cytotoxicity testing with the human liver cell line HepG2. The potential for synergistic activity with a standard antibiotic was also probed. Palmitic acid and stearic acid prepared in carrier 4 (PA4 and SA4, respectively) were identified as most active lipids (MIC against MDR Staphylococcus epidermidis was 0.5 and 0.25 μg/mL, respectively; MIC against vancomycin resistant Enterococcus faecalis (VRE) was 2 and 0.5 μg/mL, respectively). Cholesteryl linoleate formulated with carrier 3 (CL3) exhibited activity against the S. epidermidis strain (MIC 1 μg/mL) and a Pseudomonas aeruginosa strain (MIC 8 μg/mL) and lowered the vancomycin MIC for VRE from 32-64 μg/mL to as low as 4 μg/mL. At 90 μg/mL PA4, SA4, and CL3 effected less than 5 % hemolysis over 3 h and PA4 and CL3 did not exhibit significant cytotoxic activity against HepG2 cells when applied at 100 μg/mL over 48 h. Our results showed that selected fatty acids and cholesteryl esters packaged with phospholipids exhibit antibacterial activity against Gram-positive and Gram-negative bacteria and may augment the activity of antibiotics. Bactericidal activity could be unlinked from hemolytic and cytotoxic activity and the type of phospholipid carrier greatly influenced the activity. Thus, fatty acids and cholesteryl esters packaged in liposomes may have potential as novel lipophilic antimicrobial agents.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27391402</pmid><doi>10.1186/s13104-016-2138-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-0500
ispartof BMC research notes, 2016-07, Vol.9 (1), p.337-337, Article 337
issn 1756-0500
1756-0500
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4938966
source MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Care and treatment
Cholesterol Esters - pharmacology
Cross Infection - drug therapy
DNA, Bacterial - analysis
DNA, Bacterial - genetics
Drug Combinations
Drug Compounding
Drug Resistance, Multiple, Bacterial
Drug Synergism
Enterococcus faecalis - drug effects
Enterococcus faecalis - genetics
Enterococcus faecalis - growth & development
Erythrocytes - drug effects
Esters
Fatty acids
Fatty Acids, Nonesterified - pharmacology
Fluorescent Dyes
Health aspects
Hemolysis - drug effects
Hep G2 Cells
Humans
Liposomes - chemistry
Microbial drug resistance
Microbial Sensitivity Tests
Organic Chemicals
Properties
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - genetics
Pseudomonas aeruginosa - growth & development
Sheep
Staphylococcus epidermidis - drug effects
Staphylococcus epidermidis - genetics
Staphylococcus epidermidis - growth & development
Vancomycin - pharmacology
title Assessment of free fatty acids and cholesteryl esters delivered in liposomes as novel class of antibiotic
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A47%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20free%20fatty%20acids%20and%20cholesteryl%20esters%20delivered%20in%20liposomes%20as%20novel%20class%20of%20antibiotic&rft.jtitle=BMC%20research%20notes&rft.au=Cheung%20Lam,%20Annie%20H&rft.date=2016-07-08&rft.volume=9&rft.issue=1&rft.spage=337&rft.epage=337&rft.pages=337-337&rft.artnum=337&rft.issn=1756-0500&rft.eissn=1756-0500&rft_id=info:doi/10.1186/s13104-016-2138-8&rft_dat=%3Cgale_pubme%3EA468885761%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1803797628&rft_id=info:pmid/27391402&rft_galeid=A468885761&rfr_iscdi=true